Find comprehensive information on gynecomastia diagnosis, including clinical documentation, medical coding, ICD-10 codes, SNOMED CT codes, and billing guidelines. Learn about the diagnostic criteria, differential diagnosis, and treatment options for gynecomastia. This resource is designed for healthcare professionals, medical coders, and clinicians seeking accurate and up-to-date information on gynecomastia management and documentation in a healthcare setting.
Also known as
Hypertrophy of breast
Includes gynecomastia and other breast enlargements.
Disorders of puberty
May include gynecomastia as a related symptom in some cases.
Ovarian dysfunction
Certain ovarian disorders can cause hormonal imbalances leading to gynecomastia.
When to use each related code
| Description |
|---|
| Enlarged male breast tissue |
| Pseudogynecomastia |
| Pubertal gynecomastia |
Using N62 without laterality (N62.0-N62.4) or underlying cause documentation leads to claim denials and inaccurate data.
Failing to code drug-induced gynecomastia (N62.1) when applicable misses key patient data and impacts pharmacy analytics.
Miscoding physiologic pubertal gynecomastia as pathological (N62) creates inaccurate reporting and potential overtreatment.
Q: What are the most effective diagnostic workup strategies for differentiating pubertal gynecomastia from more serious underlying causes in adolescent males?
A: Differentiating pubertal gynecomastia, a common benign condition, from pathological causes requires a thorough clinical evaluation. Start with a detailed patient history focusing on puberty onset, drug use (including over-the-counter medications and supplements), family history of endocrine disorders, and any testicular symptoms. A comprehensive physical exam should assess testicular size and consistency, presence of any other secondary sexual characteristics, and signs of systemic illness. For persistent gynecomastia lasting longer than 2 years or accompanied by concerning features like rapid growth, pain, testicular abnormalities, or systemic symptoms, consider implementing further investigations like serum hormone levels (LH, FSH, testosterone, estradiol, hCG, and prolactin), liver function tests, and potentially imaging studies such as testicular ultrasound or chest imaging if clinically indicated. Explore how age-specific reference ranges for hormone levels can aid in accurate interpretation. In complex cases, referral to an endocrinologist is warranted for specialized management.
Q: How can clinicians accurately distinguish gynecomastia from pseudogynecomastia (lipomastia) during a physical exam and what additional imaging techniques might be helpful in challenging cases?
A: Distinguishing gynecomastia, a glandular proliferation, from pseudogynecomastia (lipomastia), which is fat deposition, relies on careful palpation. In gynecomastia, a firm, concentric, mobile disc of tissue is palpable beneath the areola, often with a palpable edge. In pseudogynecomastia, the tissue feels softer and more diffuse without a discrete edge. If the distinction remains unclear, consider implementing breast ultrasound as it can effectively differentiate glandular tissue from adipose tissue. Mammography is generally not recommended in adolescents due to radiation exposure and lower sensitivity in detecting glandular tissue in younger patients. Learn more about the utility of ultrasound in evaluating breast masses in male patients.
Patient presents with a chief complaint of enlarged breast tissue, consistent with gynecomastia. Onset of breast development was [Onset - e.g., gradual, sudden], [Duration - e.g., over the past six months, two years]. The patient reports [Presence or absence of pain - e.g., tenderness to palpation in the bilateral subareolar region, no pain]. [Unilateral or bilateral - e.g., Bilateral, symmetrical; Unilateral left-sided] firm, palpable glandular tissue is noted beneath the areola and extending [Extent - e.g., 2 cm in diameter bilaterally, 5 cm in diameter on the left side]. No nipple discharge or skin changes observed. The patient denies galactorrhea. Tanner stage [Tanner stage]. Review of systems includes [Pertinent positives and negatives related to endocrine function, medication use, and other potential causes, e.g., no changes in libido, no weight gain or loss, no use of anabolic steroids or estrogenic medications, no history of liver or kidney disease]. Current medications include [List all medications]. Family history is negative for breast cancer. Physical examination reveals [Overall physical findings - e.g., otherwise normal male habitus, normal testicular volume]. Differential diagnosis includes pseudogynecomastia (lipomastia), breast cancer, and other hormonal imbalances. Initial assessment suggests [Likely cause, if identifiable - e.g., pubertal gynecomastia, drug-induced gynecomastia]. Plan includes [Laboratory tests if indicated - e.g., serum testosterone, estradiol, LH, FSH, hCG; liver function tests; renal function tests]. Patient education provided regarding the possible causes of gynecomastia, expected course, and treatment options. Follow-up scheduled in [Timeframe - e.g., six weeks, three months] to monitor for changes and discuss further management, which may include [Potential treatment options - e.g., observation, medication adjustment if applicable, referral to endocrinology, surgical consultation]. ICD-10 code: N73.3.